JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dooley, C. T.
Right arrow Articles by Toll, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dooley, C. T.
Right arrow Articles by Toll, L.

Vol. 283, Issue 2, 735-741, 1997

Binding and In Vitro Activities of Peptides with High Affinity for the Nociceptin/Orphanin FQ Receptor, ORL11

Colette T. Dooley, Christine G. Spaeth, Ilona P. Berzetei-Gurske, Karen Craymer, Indira D. Adapa, Susan R. Brandt, Richard A. Houghten2 and Lawrence Toll3

Torrey Pines Institute for Molecular Studies, San Diego, California (C.T.D., C.G.S., R.A.H) and SRI International, Menlo Park, California (I.P.B-G., K.C., I.D.A., S.R.B., L.T.).

Fifteen hexapeptides having high affinity for the opioid-like receptor ORL1 were identified from a combinatorial library containing more than 52 million different hexapeptides. The five compounds with the highest affinity were characterized further by use of a variety of in vitro models. Binding studies indicated that these five peptides have affinity for ORL1 in the nanomolar range, similar to the recently discovered endogenous ligand called nociceptin and orphanin FQ (N/OFQ). The activity of these compounds was investigated in three different assays: stimulation of [35S]GTPgamma S binding and inhibition of forskolin-stimulated cAMP accumulation in Chinese hamster ovary cells transfected with ORL1, and inhibition of electrically induced contractions in the mouse vas deferens. In each assay, the five hexapeptides acted as partial agonists. The EC50 values for stimulation of [35S]GTPgamma S binding and inhibition of cAMP accumulation were in the range of that for N/OFQ, but maximal effects ranged from 70 to 90% of N/OFQ in the cAMP assay, and 30 to 60% of N/OFQ in the GTPgamma S assay. The positive hexapeptides identified were found to have minimal structural similarity to N/OFQ. The peptides are positively charged, which could enable them to bind to the negatively charged second extracellular loop thought to be a likely binding site for N/OFQ.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J BiochemHome page
N. Akuzawa, S. Takeda, and M. Ishiguro
Structural Modelling and Mutation Analysis of a Nociceptin Receptor and its Ligand Complexes
J. Biochem., June 1, 2007; 141(6): 907 - 916.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. V. Khroyan, N. T. Zaveri, W. E. Polgar, J. Orduna, C. Olsen, F. Jiang, and L. Toll
SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a Novel Mixed Nociceptin/Orphanin FQ/{micro}-Opioid Receptor Partial Agonist: Analgesic and Rewarding Properties in Mice
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 934 - 943.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. R. Kapusta, C. Thorkildsen, V. A. Kenigs, E. Meier, M. M. Vinge, C. Quist, and J. S. Petersen
Pharmacodynamic Characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a Novel, Functionally Selective Nociceptin/Orphanin FQ Peptide Receptor Partial Agonist with Sodium-Potassium-Sparing Aquaretic Activity
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 652 - 660.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. R. Kapusta, M. A. Burmeister, G. Calo', R. Guerrini, H. B. Gottlieb, and V. A. Kenigs
Functional Selectivity of Nociceptin/Orphanin FQ Peptide Receptor Partial Agonists on Cardiovascular and Renal Function
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 643 - 651.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Carra, A. Rizzi, R. Guerrini, T. A. Barnes, J. McDonald, C. P. Hebbes, F. Mela, V. A. Kenigs, G. Marzola, D. Rizzi, et al.
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a Highly Potent and Selective Agonist of the Nociceptin/Orphanin FQ Receptor
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1114 - 1123.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Corbani, C. Gonindard, and J.-C. Meunier
Ligand-Regulated Internalization of the Opioid Receptor-Like 1: A Confocal Study
Endocrinology, June 1, 2004; 145(6): 2876 - 2885.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. F. Zaratin, G. Petrone, M. Sbacchi, M. Garnier, C. Fossati, P. Petrillo, S. Ronzoni, G. A. M. Giardina, and M. A. Scheideler

J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 454 - 461.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Rizzi, A. Rizzi, R. Bigoni, V. Camarda, G. Marzola, R. Guerrini, C. De Risi, D. Regoli, and G. Calo'
[Arg14,Lys15]Nociceptin, a Highly Potent Agonist of the Nociceptin/Orphanin FQ Receptor: in Vitro and in Vivo Studies
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 57 - 63.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
J. S. Mogil and G. W. Pasternak
The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family
Pharmacol. Rev., September 1, 2001; 53(3): 381 - 415.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Berger, G. Calo', E. Albrecht, R. Guerrini, and M. Bienert
[Nphe1]NC(1-13)NH2 Selectively Antagonizes Nociceptin/Orphanin FQ-Stimulated G-Protein Activation in Rat Brain
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 428 - 433.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
L. Mouledous, C. M. Topham, C. Moisand, C. Mollereau, and J.-C. Meunier
Functional Inactivation of the Nociceptin Receptor by Alanine Substitution of Glutamine 286 at the C Terminus of Transmembrane Segment VI: Evidence from a Site-Directed Mutagenesis Study of the ORL1 Receptor Transmembrane-Binding Domain
Mol. Pharmacol., March 1, 2000; 57(3): 495 - 502.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
J. A. J. Becker, A. Wallace, A. Garzon, P. Ingallinella, E. Bianchi, R. Cortese, F. Simonin, B. L. Kieffer, and A. Pessi
Ligands for kappa -Opioid and ORL1 Receptors Identified from a Conformationally Constrained Peptide Combinatorial Library
J. Biol. Chem., September 24, 1999; 274(39): 27513 - 27522.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. Mollereau, L. Mouledous, S. Lapalu, G. Cambois, C. Moisand, J.-L. Butour, and J.-C. Meunier
Distinct Mechanisms for Activation of the Opioid Receptor-Like 1 and kappa -Opioid Receptors by Nociceptin and Dynorphin A
Mol. Pharmacol., February 1, 1999; 55(2): 324 - 331.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
L. Mouledous, C. M. Topham, H. Mazarguil, and J.-C. Meunier
Direct Identification of a Peptide Binding Region in the Opioid Receptor-like 1 Receptor by Photoaffinity Labeling with [Bpa10,Tyr14]Nociceptin
J. Biol. Chem., September 15, 2000; 275(38): 29268 - 29274.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.